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PERSPECTIVES IN RENAL MEDICINE
Pregnancy in renal disease
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Until the 1980s, opinions conflicted concerning the reciprocal
influence of kidney disease on the outcome of pregnancy and of
pregnancy on the natural course of maternal renal disease.
Previous studies [1—5] reported an abnormally high incidence of
fetal death, but no clear picture of the factors related to fetal
prognosis emerged, and whereas most authors reported a fre-
quent deleterious effect of pregnancy on maternal renal function
[3—5], others found no such adverse influence [1, 2]. However,
most of the older studies were anecdotal or bore on limited series
of patients, and reported on pregnancies that took place before
current advances in prenatal care and antihypertensive therapy
had been developed.
In the past 15 years, several studies using large numbers of
patients with well defined types of kidney diseases [6—121 have
considerably clarified the problem. They suggest that a clear
distinction must be made between: (i) patients affected by primary
renal diseases and those in whom renal involvement is part of a
systemic disease; and (ii) patients having preserved renal function
and normal blood pressure at conception and those with already
impaired renal function and/or hypertension at the start of
gestation. From these clinical studies, it was possible to identify
factors that influence fetal and maternal prognosis, thus providing
a basis for proper preconception counseling and optimal manage-
ment of pregnancy [131. In addition, experimental models shed
light on the modifications of renal hemodynamics induced by
gestation in animals with normal or altered renal function.
Because impaired renal function at conception markedly in-
creases the risk of fetal and maternal complications, problems
arising in pregnant women with chronic renal failure who are on
maintenance dialysis or following kidney transplantation will be
specifically addressed.
PREGNANCY-INDUCED CHANGES IN RENAL
HEMODYNAMICS
Experimental models
The pregnant rat is a suitable animal model for study of the
gestational changes in renal hemodynamics, as recently reviewed
by Baylis [14]. Pregnancy induces a state of sustained renal
vasodilation, owing to the concomitant reduction in tone of both
afferent and efferent arterioles, so that the increase in glomerular
filtration rate (GFR) is not associated with an increase in glomer-
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ular capillary pressure (PGC) [15] and no glomerular sclerosis
ensues even after repetitive gestations [161. Thus, pregnancyperse
does not induce any deterioration in renal function in animals
with a normal kidney. Moreover, gestation does not alter the
course of various models of experimental renal disease such as
gentamicin-induced nephropathy [171, adriamycin nephropathy
[18] or of a normotensive model of glomerulonephritis [19]. Even
in rats submitted to subtotal renal ablation, there was no gesta-
tion-induced worsening of renal function or accelerated glomer-
ulosclerosis [20, 21]. However, acute blockade of nitric oxide
(NO) inhibits pregnancy-induced renal vasodilation [22]. When
pregnancy was superimposed on chronic blockade of nitric oxide
(NO) hypertension developed, renal function declined, and endo-
thelial damage occurred, as seen in preeclampsia [23, 241. In
summary, none of the animal models of normotensive renal
disease had their gestation associated with any acute or chronic
worsening of the underlying renal injury [25]. By contrast, when
systemic hypertension is produced, such as by chronic NO block-
ade, renal and peripheral gestational vasodilation is blunted, thus
suggesting a key role for NO in the hemodynamic adaptations to
pregnancy [261.
Clinical data
In the healthy pregnant woman, effective renal plasma flow
evaluated by PAH clearance increases by 80%, and GFR mea-
sured by inulin clearance increases by 50% from the end of the
first trimester [25, 27]. These changes remain throughout preg-
nancy, and return to pre-pregnancy values at the end of pregnancy
[28, 29]. Accordingly, serum creatinine (Sr) concentration de-
creases by about 10% in the first trimester and 30% in the last
trimesters, with mean Scr values declining from 73 (0.82 mg/dl)
pre-pregnancy to 65, 51 and 47 jimol/liter (0.73, 0.58 and 0.53
mg/dl), respectively, in the successive trimesters [27]. Therefore, a
Scr value of 75 j.tmol/liter (0.85 mg/dl) may be indicative of
incipient renal failure in pregnancy. Of note, formulae that have
been proposed to estimate GFR from the Sr level, such as the
Cockeroft-Gault formula [301, arc not applicable during preg-
nancy [31]. Creatiriine clearance (Car) can be estimated using
such formulae only in the preconception state or post-partum.
Intravenous infusion of amino acids evokes an additional increase
in GFR, indicating that renal hemodynamic reserve may be
elicited in healthy pregnant women [32], but this effect was not
found following an oral protein load [33].
In normal pregnancy, maternal extracellular fluid volume,
especially plasma volume, continuously increases during gestation
in order to provide adequate blood supply to the feto-placental
unit, the increment being about 40% in plasma volume in the third
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trimester [25, 27]. Concurrently, serum albumin concentration
physiologically decreases to 30 to 35 g/liter from the second
trimester up to delivery. A significant relationship has been shown
between the extent of plasma volume expansion and fetal growth
[34], whereas preeclampsia is associated with a reduction in
plasma volume [34, 35]. Parallel to gestational vasodilation, a
decrease in blood pressure is observed in the first two trimesters
of normal pregnancy, together with a reduced responsiveness to
the pressor effects of angiotensin II [36].
PRIMARY GLOMERULAR DISEASES
Our present knowledge of fetal and maternal outcome in
women with primary glomerulonephritis (GN) is mainly based on
data from seven recent large studies [6—11] cumulating 906
pregnancies in 558 women diagnosed with various types of
biopsy-proven primary GN. Of note, in these studies the majority
of patients had normal or near-normal renal function, and the
proportion of women with serum creatinine higher than 125
jimol/liter (1.4 mg/dl) at conception was less than 5%.
Fetal outcome
Overall fetal loss (not considering therapeutic abortions) was
21%, including 13% of perinatal deaths after the 26th gestational
week, and the rate of pre-term delivery was 19%. Initially it was
believed that the variety of glomerular disease had an influence
per se on fetal outcome, since fetal loss and the prematurity rate
differed among the various histological groups [37] as shown in
Table 1. However, it subsequently appeared that risk factors
associated with the renal disease account for the variable fetal
outcome observed in the different types of glomerulonephritis.
Focal glomendoscierosis and minimal change nephrolic syn-
drome. In focal glomerulosclerosis, an especially high fetal death
rate (45%) together with a high incidence of premature delivery
and intrauterine growth retardation (IUGR) was reported by the
Melbourne group in patients who primarily had overt nephrotic
syndrome together with hypertension at conception [38]. By
contrast, European groups (including ours) reported a lower rate
of fetal complications, but fewer patients had florid nephrotic
syndrome, impaired renal function or hypertension early in preg-
nancy [7, 9, 10]. An essentially good fetal outcome was reported in
minimal change nephrotic syndrome [9, 12], at least in women
whose pregnancy took place when nephrotic syndrome was in
remission.
IgA glomerulonephropathy. In IgAGN, the most frequent variety
of primary GN, most groups report a low incidence of fetal
complications, with a fetal loss rate not exceeding 7% to 13%
[8—10, 39, 40]. A higher incidence of late intrauterine or perinatal
deaths was reported by others, but such an adverse fetal outcome
was mainly observed in patients with preexisting hypertension
and/or impaired renal function [11, 41]. The presence of severe
vascular lesions on kidney biopsy was highly predictive of prema-
turity and fetal loss [42].
Membranous glomerulonephropathy. In patients with membra-
nous GN, three studies report a low incidence ( 10%) of fetal
loss [8, 9, 12], but a less favorable outcome mainly due to first
trimester spontaneous abortions was reported by three others [9,
43, 44] in patients having overt nephrotic syndrome and/or
hypertension from the onset of gestation.
Memhranoprol(ferative glomerulopathy. A high incidence of fetal
complications was universally reported in women with membrano-
proliferative GN type I, with a mean fetal death rate of 25% [9, 11,
12]; most patients had preexisting nephrotic syndrome, hyperten-
sion and/or impaired renal function. In the dense intramembra-
nous deposit (type II) variety, a favorable fetal outcome was
reported in patients with preserved renal function [45, 46].
Acute post-streptococcal GN. Acute post-streptoeoccal GN com-
plicating pregnancy is an unusual event. In the few eases docu-
mented by kidney biopsy [47, 48], acute GN presented as sudden
occurrence of proteinuria and heniaturia in late pregnancy, the
diagnosis being made on high titers of antistreptolysins, antistrep-
tokinase, and decreased C3 serum level. The outcome of gestation
was successful and recovery of maternal renal function was
complete.
Thus, the presently accepted concept is that fetal prognosis is
not determined by the type of glomerular diseaseperse, but by the
presence or absence of risk factors associated with nephropathy,
namely nephrotic-range proteinuria, hypertension and/or im-
paired renal function present at conception or early in pregnancy
[9, 13, 49].
Ncphrotic-range proteinuria with marked hypoalbuminemia,
when present from the first trimester of gestation, is an important
factor of spontaneous abortion, prematurity and IUGR. A rela-
tionship between the degree of hypoalbuminemia and low birth-
weight was reported by Studd and Blainey [50] and Barcelo et al
[101. By contrast, no significant adverse fetal outcome occurred
when the nephrotic syndrome developed later in pregnancy [9,
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Table 1. Fetal outcome of pregnancies in women with primary glomcrulonephritis
Cumulative data from 6 studies [6—il]. Therapeutic abortions were excluded from calculation of pregnancy Outcome. Data are from Imbasciati and
Ponticelli Am J Nephrol 11:353; 1991) used with permission.
The series of Surian et al [7] was not considered since it does not include early spontaneous abortion.
h Referred to fetuses > 26 weeks
C Excluding the series of Abe et al [9], who do not report data on preterm deliveries and on outcomes of renal disease for each type of nephritisd Including focal and diffuse proliferative nephritis [6, 9, 12].
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49]. Corticosteroids, in steroid-sensitive forms of nephrotic syn-
drome, may improve this prognosis [48]. No developmental
abnormality has been reported in neonates born to mothers who
had been treated with corticosteroids or even cyclophosphamide
during gestation [12, 51], but cyclophosphamide should preferably
be avoided in the first trimester because it may be teratogenic
when given during early pregnancy [52].
The adverse effect of hypertension on fetal outcome has long
been recognized [53, 54], as the overall fetal death rate is two to
three times higher in hypertensive than in normotensive pregnarl-
cies [7, 8—10]. However, this adverse effect manifests essentially
when high blood pressure is present at conception or develops
early in pregnancy, and therapeutic control of hypertension
considerably improves fetal outcome [9, 11]. Hypertension devel-
oping late in pregnancy, even in the context of superimposed
preeclampsia, usually has no deleterious impact on fetal outcome
[9, 37]. Finally, impaired renal function appears to be the most
deleterious factor in fetal outcome, all the more as it is most often
associated with hypertension [9, 37]. Indeed, risk factors have
additive effects, the most severe combination being impaired renal
function together with hypertension and nephrotic-range protein-
uria.
Influence of pregnancy on the course of primary GN
Increased protein excretion during pregnancy in women with
preexisting GN is a common—although not constant—feature.
However, such an increase is most often transient and usually
reverses post-partum, because in a number of cases it only
corresponds to superimposed preeclampsia [7, 9, ii]. Of note,
pregnancy did not induce relapse of the nephrotic syndrome in
patients with antecedent nephrosis who were in remission at
conception [9, 55, 56]. Differential diagnosis is often difficult
between onset of GN and preeclampsia when proteinuria associ-
ated with hypertension first manifests during pregnancy. An
abnormally early onset of proteinuria and hypertension in preg-
nancy and their persistence beyond three months after delivery is
suggestive of underlying GN [57].
Worsening of preexisting hypertension is observed in only 10 to
20% of GN patients and new-onset hypertension occurs in about
20% of pregnancies [6, 9—111. When a pregnancy has been
complicated by hypertension, there is an increased risk of recur-
rent hypertension in subsequent pregnancies and of development
of permanent hypertension in the future, especially in patients
with IgAGN [9, 41].
The most debated issue has long been whether pregnancy exerts
a deleterious effect on the course of underlying GN [58]. Most
early studies [1—4] and some recent ones [11, 59, 601 report
irreversible deterioration of maternal renal function in pregnancy
as being a frequent event, whereas most recent studies report such
deterioration to be infrequent and indicate that pregnancy per se
does not alter the natural course of maternal disease [6—9, 61].
Women with preserved or mildly decreased renal function
manifest the physiological increase in OFR [61. A transient,
usually reversible, rise in Scr is often observed in late pregnancy,
but an accelerated, irreversible deterioration of maternal renal
function is infrequent, and is only observed in patients with
already impaired renal function, severe hypertension and/or heavy
proteinuria at conception, especially those with IgAGN or mem-
branoproliferative ON [6—li].
In the long term, concordant data from recent reports suggest
Time from clinical onset of renal disease, years
Fig. 1. Actuarial curves of renal survival free of end-stage renal failure in
360 women with primary glomerulonephritis and serum creatinine < 110
mol/liter at conception, of whom 171 were pregnant at least once (P+;
heavy line) and 189 did not conceive (P—, light line) after clinical onset of
renal disease. (Reprinted with permission from Jungers et al, Lance!
346:1122, 1995).
that pregnancy has no deleterious effect on maternal renal disease
when renal function is normal or near-normal at conception [6—9,
621. Further evidence of this was provided by controlled studies.
As reported by Barcelo et a!, at the end of a five-year follow-up
period the incidence of proteinuria, hypertension and renal
failure was similar in 48 women with various types of primary ON
who had been pregnant and in 36 who did not conceive [10].
Similarly, initial and final GFR rates did not differ between 36
women with IgAGN who had been pregnant and 35 who did not
conceive over a five-year observation period as reported by Abe
[63]. Decisive evidence was provided by a recent study from our
group, comparing the incidence of end-stage renal failure (ESRF)
among 360 women with various histological forms of primary ON
who all had normal or near-normal renal function [Sr  110
j.tmol/liter (1.24 mg/dl)] at conception or at presentation, who
were followed for a mean duration of 15 years [64]. Actuarial
renal survival curves did not differ significantly between 171
women who became pregnant after clinical onset of GN and 189
who did not conceive (Fig. 1). Furthermore, in a case-control
analysis, pregnancy did not emerge as a risk factor for progression
to ESRF whereas hypertension and type of GN were major
determinants.
PRIMARY NON-CLOMERULAR KIDNEY DISEASES
The following reports on the various types of non-glomerular
kidney diseases include mainly patients with preserved renal
function, but also some patients with impaired renal function.
Reflux nephropathy
Reflux nephropathy is one of the most common renal diseases
encountered in women of childbearing age. This nephropathy is
frequently associated with urinary tract infection and hyperten-
sion; chronic renal failure often develops in the third and fourth
decades of life [65]. Recently updated reports from the group of
Kincaid-Smith [66] and our own group [67, 68] cumulate 697
pregnancies in 290 women with reflux nephropathy. The overall
fetal loss rate was about 12% in both studies, which is markedly
lower than that observed in women with glomerular diseases [9,
37]. Urinary tract infection (UTI) was responsible for frequent
>
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morbidity but only resulted in deleterious consequences on fetal
outcome in a very limited number of cases. The great majority of
acute pyelonephritic episodes occurred in patients in whom
vesicoureteral reflux was still present at the time of conception,
whereas upper UTI recurred in very few women who had under-
gone surgical correction of vesicoureteral reflux prior to becoming
pregnant [66, 68]. Therefore, it may be advisable to consider
prophylactic ureterovesical reimplantation in women with persis-
tent vesicoureteral reflux who contemplate pregnancy, at least in
those who experienced repeated pyelonephritic episodes in their
adult life [681.
Hypertension was of much more consequence to fetal progno-
sis. In our series, the relative risk of fetal loss was nearly five times
higher in hypertensive than in normotensive patients, and im-
paired renal function at conception was the major risk factor,
inasmuch as hypertension was most often concomitant [68]. A
similarly adverse effect of concomitant hypertension and renal
failure in women with reflux nephropathy has been reported by
others [69].
Nephrolithiasis
In view of the increased urinary calcium excretion in gravidas
which results in urine supersaturation for calcium oxalate and/or
phosphate [70], one should anticipate that pregnancy favors
calcium stone development. In fact, the concomitant increase in
crystallization inhibitors, namely magnesium, citrate and nephro-
calcin, that occurs during pregnancy [71] largely counterbalances
gestational hypercalciuria and prevents de novo formation of
stones during gestation.
Therefore, problems arising from urolithiasis in pregnancy
essentially correspond to previously formed stones [72]. The most
frequent complications are renal colic and UTI, both of which
may result in premature labor. Physiological ureteropelvic dilation
probably favors migration of preexisting kidney stones. Ultra-
sonography is the best diagnostic technique because it does not
expose the fetus to ionizing radiation. Conservative management
alone results in spontaneous passage of about two thirds of stones.
In the case of intractable pain, severe infection, premature
contractions or deterioration of renal function, urological inter-
vention may be needed [72]. Cystoscopy allows either removal of
the stone by ureteroscopy or to relieve obstruction by placing a
double J stent catheter [73, 741 that is maintained until delivery
under prolonged antibacterial protection. Whenever possible
lithotripsy is deferred to the post partum period, because shock
waves are potentially harmful to the fetus [74].
Pregnancy in women with cystinuria may be a difficult problem.
Because of the possible teratogenic effects of d-penicillamine or
other sulfhydriles to the fetus, it is best to avoid using such drugs
during pregnancy, especially during the first trimester [75, 761.
Prevention of cystine stone formation during pregnancy should
rely on high diuresis and alkalinization by means of sodium
bicarbonate [76], or best potassium citrate in hypertensive pa-
tients [72].
Autosomal dominant polycystic kidney disease (ADPKD)
The outcome of pregnancy appears essentially uneventful in
ADPKD patients because the great majority of such women in the
childbearing age have normal renal function. In recent studies, the
mean age of female ADPKD patients was 39 years at the time of
incipient renal failure [77] and 55 years at end-stage renal failure
(ESRD) [781. In three large series [9, 79, 80] the overall live birth
rate in ADPKD women was nearly 85%. Hypertension when
present early in gestation was the most important factor of
adverse fetal prognosis and was often associated with preeclamp-
sia and recurrence in subsequent gestations [9, 801. Urinary tract
infection was an infrequent complication and had little conse-
quence on fetal prognosis. The number of gestations had no
influence on maternal renal function in two studies [9, 79],
although Gabow et al [811 reported a higher incidence of renal
failure in ADPKD women who had three pregnancies or more;
this effect, however, was significant only in hypertensive patients
and the age of entry into ESRD was not influenced by the number
of pregnancies. Screening for unruptured intracranial aneurysms
by magnetic resonance angiography is advisable before concep-
tion in women having a family history of intracranial aneurysms in
order to propose prophylactic repair (if indicated), and to avoid
vaginal birth [82].
Other hereditary diseases
Problems of pregnancy in women with renal hereditary diseases
have been recently reviewed [831.
Alport's syndrome. In the X-linked form of hereditary nephritis
(Alport's syndrome) [84], carrier females usually have no or only
mild urinary abnormalities during the childbearing years and
pregnancy is usually uneventful, but there is a report of two sisters
who developed rapidly progressive crescentic glomerulonephritis
during pregnancy [85]. In the variant associated with macrothrom-
bocytopenia and altered platelet functions gestation may be
complicated by bleeding problems at delivery [84].
Tuberous sclerosis. In tuberous sclerosis retroperitoneal hemor-
rhage may result from bleeding angiomyolipomas during gestation
[86]. In von Hippel-Lindau disease, pheochromocytomas consti-
tute a risk of severe complications in pregnancy, especially at
delivery [87]. Affected women should be screened before conceiv-
ing in order to rule out presence of pheochromocytoma, renal cell
carcinoma and/or hemangioblastoma involving the central ner-
vous system [87, 881.
In several of these severe diseases antenatal diagnosis is already
available [83, 89], which gives a basis for collegiate counseling with
the family and involves the nephrologist, the geneticist and the
obstetrician to consider the termination of pregnancy [83].
DIABETIC NEPHROPATHY
Because insulin-dependant (type I) diabetes mellitus is a com-
mon disease, problems arising in pregnancy are of frequent
concern. The presence of diabetic nephropathy impairs fetal
outcome because factors related to overt microangiopathy and
glycemic control add their deleterious effects to those of protein-
uria and hypertension, especially in patients with already impaired
renal function [90—92].
In diabetic patients with or without renal involvement, maternal
hyperglycemia causes fetal hyperglycemia that results in fetal
hyperinsulinemia, a factor of macrosomia and congenital malfor-
mations. In earlier reports from the Joslin Clinic [91] 40% of
neonates were large for gestational age, 9% had congenital
abnormalities and 8% had respiratory distress syndrome. How-
ever, careful glycemic control and advances in obstetrical and
neonatal care have improved fetal survival to 90% or more in
diabetic patients with normal or near-normal renal function [92],
and recent case-control studies provide evidence that pregnancy
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does not accelerate the onset [93, 94] or progression [95] of
diabetic nephropathy.
By contrast, several groups have reported increased maternal
morbidity and complicated fetal outcome in patients with overt
diabetic nephropathy [91, 92, 96—98]. In all of these studies there
was a high incidence of prematurity (30 to 71%), intrauterine
growth retardation (16 to 22%), respiratory distress syndrome (19
to 25%) and congenital abnormalities (5 to 11%). No abnormally
rapid worsening of maternal renal disease was observed in
patients whose renal function was normal or near normal, even if
virtually all patients experienced a marked, but reversible, in-
crease in proteinuria and blood pressure during pregnancy [90]. In
addition, successful pregnancies have been reported in diabetic
patients with well-functioning kidney grafts after renal [99] or
combined pancreas-kidney transplantation [100].
Fetal and maternal outcomes appear to be much more com-
promised in diabetic patients with overt nephropathy and im-
paired renal function. Studies specifically devoted to diabetic
women with impaired renal function are few. A poor outcome was
reported by Biesenbach, Stoger and Zazgornik in four women
with diabetic nephropathy and impaired renal function, all of
whom experienced an accelerated progression toward ESRD
within a few years [101]. Similarly, Kimmerle et al observed an
accelerated deterioration in 10 women whose renal function was
already impaired, with S up to 215 1itmol/liter (2.43 mg/dl), all of
whom were hypertensive; in two women with renal transplants
and Ccr 35 mi/mm in early pregnancy there was accelerated
transplant rejection [97]. Recently, Purdy et al reported an
irreversible, accelerated progression of renal failure in 5 of ii
diabetic women whose 5Cr at onset of pregnancy ranged from 124
to 150 tmol/liter (1.4 to 1.7 mg/dl) [102]. Thus, pregnancy should
be preferably discouraged in diabetic patients with significantly
impaired renal function [97, 101, 1021.
Management of pregnancy in patients with diabetic nephropa-
thy has been recently re-evaluated [90, 102]. A multidisciplinary
approach is essential, with close cooperation between the neph-
rologist, the diabetologist and the obstetrician. First of all, preg-
nancy should be planned, in order that strict control of glucose
level be achieved before conception and throughout the preg-
nancy. Hypertension should be actively treated from the start of
gestation but angiotensin-converting enzyme inhibitors (ACEIs),
if previously used, should have been withdrawn [97] in order to
avoid deleterious renal effects to the fetus, as discussed later.
Fetal ultrasonography and echocardiography should be per-
formed between 18 and 20 weeks of gestation to detect major
developmental anomalies, giving the parents the option for ter-
mination [901.
SYSTEMIC DISEASES
Pregnancy is potentially hazardous in patients with systemic
disorders because disease activity may exacerbate during gestation
and because specific risk factors related to the multisystem disease
add their effects to those of common factors associated with renal
disease.
Lupus nephropathy
As systemic lupus erythematosus (SLE) primarily affects
women of child-bearing age, the impact of SLE on pregnancy
outcome is of great concern, especially when renal involvement is
present.
It has long been accepted that lupus nephropathy has a major
adverse influence on fetal outcome, and that pregnancy often
provokes exacerbation of lupus disease. However, reports pub-
lished in the past 15 years, as recently reviewed by Hayslett [1031,
provide a less pessimistic view. The cumulative data of several
recent large studies devoted to SLE patients with renal involve-
ment [104—109] conclude that pregnancy is most often successful
and uneventful when SLE has been in stable remission for at least
one year and renal function is normal at conception. In this
context the overall success rate, excluding first-trimester abor-
tions, is between 80 to 90%, but the incidence of preterm
deliveries is higher than in non-SLE patients [110]. Even in
patients who previously had a diffuse proliferative form of lupus
nephritis, fetal outcome is most often favorable and no relapse of
lupus nephritis is observed when onset of pregnancy takes place in
a period of stable remission induced by therapy [104—111]. By
contrast, the risk of fetal loss sharply increases when pregnancy is
started in patients with active SLE, especially when the dose of
prednisone needed to control disease activity is 20 mg/day or
more. This is especially true when lupus nephritis first manifests
during pregnancy with heavy proteinuria, overt nephrotic syn-
drome, hypertension and/or impaired renal function [104, 108,
1091. In such a situation, pregnancy ends in late abortion or
stillbirth in about one half of the cases.
Opinions still differ widely as to the risk of lupus flare during
pregnancy or post-partum. Some case-control studies comparing
SLE activity in pregnant patients and in non-pregnant counter-
parts matched for age, duration and severity of lupus disease
followed for a similar period found no difference in the incidence
of lupus flares between pregnant and non-pregnant patients [112,
113], whereas another case-control study [110] and several uncon-
trolled studies [104—109, 111, 114] reported a higher incidence of
flares during pregnancy. Such discrepancies are mainly explained
by the fact that the true incidence of lupus flares in relation with
pregnancy is difficult to assess, due to the largely unpredictable
natural course of SLE independent of gestation [103]. However,
most agree that SLE activity at conception influences the risk of
relapse or exacerbation of disease activity in pregnancy. SLE
exacerbations occur frequently when SLE is active at conception
[104—108], whereas women in remission at conception have the
lowest incidence of flares [108, 111]. Coexistence of the lupus
anticoagulant or of anticardiolipin antibodies in SLE patients
results in a high risk of recurrent early abortion [115], whereas the
presence of anti-SSAJSSB antibodies is associated with the risk of
fetal congenital heart block [114].
Preconception counseling and multidisciplinary management
are essential in pregnant patients with lupus nephritis. Conception
should be preferably planned in a period of stable, sustained
remission for at least one year, when no corticosteroid therapy, or
a low maintenance dose, is needed [103, 116]. Because anticar-
diolipin antibodies interfere with embryonic implantation [117],
patients with such antibodies should either receive low-dose
aspirin (75 to 100 mg/day) [111, 114] or low-dose subcutaneous
heparin [118] from the beginning of pregnancy. Patients with
severe lupus nephritis first developing or relapsing in pregnancy
should be aggressively treated with high-dose corticostcroids
associated with cyclophosphamide if needed [108, 109, 118, 119].
Patients with SLE in stable remission during pregnancy but with a
previous history of proliferative lupus nephritis should preferably
receive a course of corticosteroids in late pregnancy or at least for
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two to three months post partum in order to prevent a late flare
of SLE [108].
Other systemic diseases
Systemic sclerosis. In patients with systemic sclerosis, pregnancy
occurring after clinical onset of the disease may result in renal
crisis with abrupt hyperreninemic hypertensive oliguric renal
failure and pulmonary hypertension [1201, although an uneventful
course of pregnancy may be observed in women with a history of
systemic sclerosis in the absence of hypertension [1211. Such
complications are responsible for a high rate of fetal loss and even
of a fatal course in the mother [1201. However, anecdotal reports
appeared of a successful fetal outcome with partial reversal of
maternal renal failure when angiotensin-converting enzyme inhib-
itors (ACEI) were given either after delivery [122] or even during
pregnancy [123]. A patient who previously had a renal crisis that
reverted with ACEIs became pregnant after withdrawal of ACEIs
and delivered a healthy child without a recurrence of hypertensive
renal failure [1241. However, ACEIs, the only effective therapy for
such renal crisis, are harmful to the fetus so that conception
should preferably be discouraged in patients with overt sclero-
derma [831.
Polyarteritis nodosa. Since polyarteritis nodosa is uncommon in
young women, no large series of pregnancies in such patients
exists. The available experience, as reviewed by Owen and Hauth
in 1989, was limited to 12 patients [1251. Of them, five were in
remission following high-dose corticosteroids and pregnancy
ended in live birth in three cases without further deterioration of
maternal renal function. In the other seven cases, the disease
initially manifested during pregnancy as severe preeclampsia; in
all of these cases both fetus and mother died. Some advocate
pregnancy termination in patients with active disease early in
pregnancy [831, but aggressive treatment may be an alternative if
the disease reveals later in pregnancy [1251. Successful pregnan-
cies have been obtained in two patients with Churg and Strauss
syndrome in clinical remission [126].
Wegener's granulomatosis. As Wegener's granulomatosis occurs
mostly in males over 50 years of age, clinical experience in
pregnancy is limited, with at best 17 cases recorded by 1996 [127,
128]. In nine patients the disease was diagnosed during pregnancy
or within a few weeks of delivery; c-ANCAs were positive in most
cases. Of the other eight patients in whom diagnosis was estab-
lished before conception, five relapsed during pregnancy. When
disease activity was controlled by corticosteroids, cyclosphospha-
mide and/or azathioprine, healthy babies were delivered [127,
129], in one case at the price of temporary hemodialysis [130].
Healthy twins were born to a patient after kidney transplantation
while on prednisone and cyclosporine [131].
Henoch-Schönlein purpura. Little is known of pregnancy in
patients with Henoch-Schönlein purpura and renal involvement.
In a recent case report, a rapidly progressive glomerulonephritis
associated with purpura and arthralgias developed at the end of
the first gestational trimester. Renal failure worsened despite
steroid therapy and oral cyclophosphamide was added from the
28th week until delivery of a premature, but otherwise normal
neonate (132].
As a conclusion, in view of the frequency and harmful conse-
quences of flares in vasculitides, pregnancy should be contem-
plated with extreme caution in patients with periarteritis nodosa
or Wegener's granulomatosis. Whenever possible the mother
should be in remission, but active disease should be treated
vigorously, including by corticosteroid pulses, azathioprine and, as
a last resource, cyclosphosphamide [83].
Thrombotic thrombocytopenic purpura and hemolytic uremic
syndrome. Thrombotic thrombocytopenic purpura (TTP) and
hemolytic uremic syndrome (HUS) are both characterized by
microangiopathic hemolytic anemia, but may be distinguished by
the following: TTP mostly develops in the second or third
trimester of pregnancy with mild renal involvement and predom-
inant extrarenal features (neurological disturbances, fever, throm-
bocytopenia), whereas HUS occurs usually in the immediate
postpartum period, with severe acute renal failure as the promi-
nent finding [133]. Both should be differentiated from the HELLP
syndrome (acronym for Hemolysis, Elevated Liver enzymes and
Low Platelet syndrome), which is associated with severe pre-
eclampsia and involves a marked increase in serum aminotrans-
ferase level. Since more than half of cases of pregnancy-associated
TTP occur before the 24th gestational week, the rate of fetal
death is very high [134]. Recurrence of TTP in subsequent
pregnancies has been reported [133]. Plasma exchanges alone or
in combination with corticosteroid therapy have dramatically
improved the prognosis in patients with the TTP/HUS syndrome
[135], allowing fetal survival even in patients with onset of the
syndrome in early pregnancy [136].
Familial Mediterranean fever. Patients with amyloidosis of famil-
ial Mediterranean fever may experience accelerated decline of
preexisting renal failure [137]. In one patient, sarcoidosis pre-
sented in pregnancy as rapidly progressive renal failure but
responded to corticosteroid therapy, with a successful fetal out-
come [138].
PREGNANCY IN WOMEN WITH IMPAIRED RENAL
FUNCTION
In contrast to women with normal or near-normal renal func-
tion who most often have a successful and uneventful outcome of
pregnancy, gestation is much more hazardous in women with
impaired renal function. Only anecdotal cases had been reported
until the past decade, but five studies have now appeared that
were specifically devoted to pregnancy in women with established
chronic renal failure [139—143]. Adding our own series at Necker
hospital which involves 43 pregnancies in 30 women [144J, the
available clinical experience now cumulates more than 200 preg-
nancies in women whose Sr level was in excess of 125 jimol/liter
(1.4 mg/dl) at conception, including about one-third with 5C >
200 jtmol/liter (2.25 mg/dl).
Fetal prognosis
Fetal loss rate, not considering first-trimester therapeutic or
spontaneous abortions, was 16% in the study of Hou, Grossman
and Madias [139] on 39 pregnancies in women whose 5Cr ranged
124 to 221 iimol/liter (1.4 to 2.5 mg/dl), 31% in the series of
Imbasciati et al [140] bearing on 19 pregnancies in women with
S, 142 to 460 mol/liter (1.6 to 5.5 mg/dl) and 27% in the recent
series of 15 pregnancies in women with GFR 42 10 mI/mm at
conception reported by Abe [143]. In addition, in six women with
reflux nephropathy, severe hypertension and S in the range of
200 to 310 j.tmol/liter (2.25 to 3.5 mg/dl) early in gestation, Becker
et al observed three perinatal deaths [69].
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A more favorable experience was subsequently reported by
Cunningham Ct al [14fl in a series of 37 pregnancies that took
place from 1972 to 1988 in patients whose preconception Sr
ranged from 124 to 832 j.rmol/liter (1.4 to 9.4 mg/dl). Of 26
pregnancies in patients with moderate renal failure [Sr at
conception 124 to 221 rmol/liter (1.4 to 2.5mgIdl), 88% ended in
live birth, whereas of 11 pregnancies in patients with severe renal
failure [S at conception 230 to 832 j.molIliter (2.6 to 9.4 mg/dl)]
only 7 (64%) succeeded, and there was a very high incidence of
preterm delivery (86%) and fetal growth retardation (43%), the
mean live-born birthweight being 1520 g [141]. Such improved
fetal prognosis in the past decade was even more apparent in a
recent cooperative study analyzing records from six referral
centers throughout the world [142]. Among 82 pregnancies, most
of which took place after 1984, in 67 women with primary renal
disease whose initial 5Cr ranged from 124 to 487 jimol/liter (1.4 to
5.5 mg/dl), the overall live birth rate was a high as 93%. Incidence
of preterm delivery was 73% and that of IUGR was 57% in
pregnancies associated with the more advanced degree of renal
failure [Sr > 220 j.tmol/liter (2.5 mg/dl) at conception] and 28
neonates required management in an intensive care neonatal unit.
In our experience the beneficial impact on fetal outcome of
current advances in obstetrics and neonatology, together with
coordinated obstetrical and nephrological management is evi-
denced [1441. Of our patients, fetal outcome was successful in
91% of pregnancies that took place after 1984 in women with
primary renal diseases, which contrasts with a success rate of only
65% in the preceding 10-year period, although the proportion of
women referred with advanced renal failure was higher in the
recent decade. In parallel, the incidence of stillbirths decreased,
whereas the proportion of successful preterm deliveries rose. The
highest SCr level associated with a successful outcome, in our
series was 270 i.rmol/liter (3.05 mg/dl), corresponding to a Ccr of
about 25 ml/min/1.73 m2 (Fig. 2). Improvement of fetal outcome
in the recent years was especially marked in patients with the most
advanced degree of renal failure. Hypertension was the major
independent risk factor related to fetal death, with a relative risk
about tenfold higher in women whose MAP was> 105 mm Hg at
conception than in those with spontaneous normotension or
therapeutically well-controlled hypertension. Holley et al also
reported hypertension as the major factor of adverse pregnancy
outcome, although they did not observe an indisputable improve-
ment in the recent years compared to previous reports, but most
of their patients had diabetic nephropathy or systemic immune
diseases [1451.
Finally, the cumulated experience presently available allows a
less pessimistic view than was held not long ago. Successful fetal
outcome may now generally be expected whenever the Sr at
conception is under 160 to 180 j.tmol/liter (1.81 to 2.03 mg/dl;
corresponding to a creatinine clearance of about 40 ml/min!i.73
m2), and is also frequent in patients with (r up to 200 to 250
.tmol/liter (2.2 to 2.8 mg/dI; corresponding to a CCr of 25 to 30
ml/min/i.73 m2), although fetal and maternal outcomes still
remain much more hazardous beyond this limit. However, in
recent years, several reports appeared of patients with advanced
renal failure at conception in whom hemodialysis or peritoneal
dialysis had to he started during pregnancy in order to limit
uremic toxicity, and who successfully delivered live infants, usually
very premature and of very low birthweight [146—150]. It must be
stressed that, in most cases, supportive therapy had to be pursued
1975—84 1985—94
Fig. 2. Outcome of 43 pregnancies in 30 women with impaired renal
function followed at Necker hospital. Fetal outcome is compared in the
1975 to 1984 and 1985 to 1994 decades with respect to serum creatinine
level at conception and primary renal disease. Open symbols denote live
births, closed symbols denote fetal death with asterisks indicating first-
trimester abortions. Renal disease is represented as follows: (O) polycys-
tic kidney disease; (A) reflux nephropathy; (7) chronic interstitial nephri-
tis; (0) IgAGN; (LI) membranous ON. (Used with permission from
Jungers et al [144].)
after delivery because deterioration of maternal renal failure was
irreversible [147, 150]. Earlier initiation of supplementing dialysis,
that is, as soon as S, exceeds 350 imol/liter (4 mg/dl), has been
reported to allow better fetal growth and prevent prematurity
[1511.
Maternal outcome
Gesiational increase in GFR, although of a lesser extent than
that seen in normal gravidas, may be observed in women with
moderately impaired renal function hut in none with severe renal
dysfunction [141, 144]. Superimposed preeclampsia is a frequent
complication in women with impaired renal function, especially
those with preexisting permanent hypertension. In this setting,
superimposed preeclampsia developed in 65% of pregnancies in
our patients [144], and in 57 to 80% in other series [139—141].
The most crucial issue is whether or not there is an increased
L
E
E
ci,C
C
cci
ci)
C)
E
ci)(I)
*A 0.49
*A 0.34
A
0.25 -
.
.
0.20
V
0.15
VA
0
0.10
878 Jungers and Chauveau: Pregnancy in renal disease
risk of irreversible worsening of maternal renal disease in patients
with already impaired renal function. Such an accelerated course
was observed in nearly half of patients whose 5Cr ranged from 142
to 257 jtmol/liter (1.6 to 2.9 mg/dl) reported by Hou et al [139]
and in the same proportion in patients with preconception S(;F
level ranging from 159 to 407 .tmol/liter (1.8 to 4.6 mgldl)
reported by Imbasciati et al l40l and in patients with preconcep-
tion GFR lower than 50 mI/mm reported by Abe [143], as well as
in all of six patients with S ranging from 200 to 310 mol/liter
(2.25 to 3.5 mg/dl) reported by Becker et a! [69]. In the study of
Cunningham et a!, such accelerated deterioration was observed in
only 5 (19%) of 26 patients with Sr < 230 j.tmol/liter (2.6 mg/dl),
contrasting with 5 (45%) of 11 patients with SCr ranging from 230
to 832 j.tmol/liter (2.6 to 9.4 mg/dl) [1411.
In our series [144], accelerated worsening of maternal disease
was observed in 7 of 30 women (23%), all of whom had severe
hypertension and heavy proteinuria at conception; all but two had
an initial 5Cr in excess of 210 imol/liter (2.37 mg/dl). As com-
pared to the preconception level, late in pregnancy a rise in Scr
was observed, of 21% as a mean, which usually reverted within
two to four months of delivery to a value slightly higher than the
preconception level. The lack of such a post partum reversal in the
SCr level was predictive of relentless accelerated progression
toward ESRF. In the cooperative study of Jones and Hayslett, the
Sr level increased from a mean value of 168 71 jimol/liter
(1.9 0.8 mg/dl) early in pregnancy to 221 115 amol/liter
(2.5 1.3 mgldl) in the third trimester, a rise of 31%. An
accelerated course toward ESRF was observed in 7 (35%) of 20
pregnancies in women whose initial S concentration was 177
mol/liter (2 mg/dl) or higher [142].
There is no clear-cut limit of renal dysfunction beyond which
the risk of accelerated deterioration sharply increases, but present
evidence suggests that the risk begins when 5Cr is in excess of 180
mol/liter (2 mgldl), and that a Sr value in excess of 250
j.mol/liter (2.8 mg/dl), or Cr below 25 ml/min/1.73 m2, is
indicative of a high potential of deterioration, particularly when
severe hypertension and/or heavy proteinuria is present, especially
in patients with primary glomerulonephritis or systemic disease.
Guidelines to optimal management of pregnancy in women with
impaired renal function are summarized in Table 2.
PREGNANCY IN WOMEN ON MAINTENANCE DIALYSIS
Pregnancy was reported as very infrequent, and both unsuccess-
ful and complicated, in women on maintenance dialysis. However,
in the recent years, a prudently more optimistic view has been
progressively emerging, in parallel with improvement in the
general condition of patients on maintenance dialysis and better
management of the dialysis patient who desires motherhood, as
recently reviewed by Hou [152].
Fertility in ESRD patients
Fertility is decreased in ESRD patients, due to uremia-associ-
ated hypothalamo-pituitaiy dysfunction resulting in ovarian dys-
function and anovulatory cycles [153, 1541. However, improved
dialysis efficacy together with correction of anemia due to the
generalized use of recombinant erythropoietin presently allows
better restoration of general condition and sexual function, and
results in an increased frequency of ovulatory cycles and aug-
mented fertility [155]. As a consequence, appropriate contracep-
tion is now needed in female dialysis patients of childbearing age
Table 2. Guidelines to optimize pregnancy Outcome ifl women with
impaired renal function
1. Full preconception counseling and planned pregnancy.
2. Closely coordinated care between nephrologist and obstetrician.
3. Management of pregnancy in a high-risk obstetric facility with
attendent neonatal intensive care unit.
4. Optimal blood pressure control from the beginning of pregnancy:
avoidance of diuretics and ACEIs; preferred use of methyldopa and
beta-receptor antagonists as first- and second-line drugs; diastolic
blood pressure no higher than 90 mm Hg and no lower than
80 mm Hg.
5. Correction of anemia: iron and folate supplementation; institution
or reinforcement of EPO therapy.
6. Prevention of metabolic acidosis and hypocalcemia.
7. Adequate protein and calorie supply.
8. Intensified surveillance of serum creatinine and urea level.
Initiation of supplemental dialysis whenever is in excess of 350—
400 jsmol/liter and/or blood urea in excess of 20 mmol/liter.
9. Intensified fetal monitoring from the 26th gestational week;
hospitalization of the patient in a high-risk obstetrical facility in the
case of premature contractions.
10. Close surveillance of maternal renal function, blood pressure and
proteinuria in the post-partum period.
__________
in order to avoid an unplanned or unwanted pregnancy, which
often carries the risk of an unsuccessful outcome, and creates
severe emotional stress in the patient [152]. The diagnosis of
pregnancy can be difficult and is frequently made late. In some
instances, pregnancy was diagnosed upon increasing anemia or
apparent resistence to recombinant erythropoietin therapy [156].
Urine pregnancy tests are of no value, even when residual urine
output is still present. Measurement of serum /3 human chorionie
gonadotrophin level is also inaccurate, so that ultrasonography is
the only valuable means to assess gestatiorial age [152].
Fetal outcome
By the end of 1993, there were about 75 isolated reports of
successful pregnancies in women on hemodialysis or peritoneal
dialysis, as reviewed by Hou [152], but few studies allow an
accurate evaluation of the frequency of gestation and its outcome
in the whole population of dialysis women. In 1980, 115 pregnan-
cies were reported among 13,000 women of childbearing age
followed in Europe; 45 ended in termination of pregnancy and of
the other 70 only 16 (23%) resulted in live birth [157]. In 1992,
Souqiyyeh et al reported a live birth rate of 30% among 27
pregnancies that occurred in 22 dialysis patients over the previous
five years [1581. More recently, Hon completed an inquiry in 194
dialysis units in the USA caring for 1281 women of childbearing
age [159]. Sixty pregnancies were reported, of which 37% resulted
in surviving infants. Interestingly, the success rate rose from 21%
prior to 1990 to 52% in 1990 to 1991, thus reflecting considerable
progress in the management of pregnant dialysis patients (Fig. 3).
Prematurity is the major problem in dialysis pregnancies, with a
continuum between mid-trimester intrauterine fetal deaths, still-
births, and premature live births [159]. Most living neonates are of
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deaths 9% "
very low birthweight, indicating the need for management of
gestation in high-risk pregnancy facilities with attendent neonatal
intensive care unit. A beneficial effect of indomethacin given in
the case of premature uterine contractions has been reported
[1501, but its prolonged use has been complicated by neonatal
anuria and stillbirth [160], and this drug should never be pre-
scribed beyond the 32th gestational week. Many nephrologists
currently discourage its use since it carries the risks of neonatal
renal failure, necrotizing enterocolitis, intracranial hemorrhage
and premature ductus arteriosus closure [161].
Polyhydramnios is common in dialysis patients, probably as a
result of the osmotic diuresis induced by the high blood urea
concentration delivered to fetal kidneys where renal function is
normal [150]. Daily dialysis with blood urea maintained under 17
mmol/liter and slow ultrafiltration has been proposed to prevent
polyhydramnios and reduce the fetal azotemic environment. In
addition, prophylactic dialysis allows easier control of hyperten-
sion and more liberal protein intake by the mother [152]. Anemia
of renal failure worsens during pregnancy, because the decline in
hematocrit due to plasma volume expansion adds its effects to the
lack of increased red cell production. A generally accepted goal is
to restore maternal blood hemoglobin level to 10 to 11 gldl by
institution or reinforcement of recombinant erythropoietin ther-
apy [1521. Of note, recombinant erythropoietin requirement usu-
ally increases by about 50% in pregnancy [148, 149, 156].
Management of dialysis in pregnancy
Managing pregnancy in dialyzed patients is a difficult task,
requiring especially close cooperation between nephrologic and
obstetric teams. Measures aimed at optimizing fetal and maternal
outcome, as discussed in detail by Hou [152], are summarized in
Table 3. Whether hemodialysis or peritoneal dialysis is the most
appropriate in pregnant patients is debated. Both techniques,
when carefully managed, appear of value and neither is clearly
better than the other. Doppler velocimetry of the uterine and
umbilical arteries at 20 to 24 weeks of gestation are of interest to
predict the risk of preeclampsia and evaluate the effect of
hemodialysis on the utero-placental and umbilical-placental cir-
culations [162, 163].
PREGNANCY IN RENAL TRANSPLANT RECIPIENTS
By contrast with patients on dialysis, in whom pregnancy still is
an infrequent event, thousands of successful gestations have
occurred in transplant recipients throughout the past four decades
[164]. A number of transplanted women even had more than one
successful pregnancy [165]. Indeed, transplantation rapidly re-
Fig. 3. Outcome of pregnancy in women on
maintenance dialysis. Thirty-six pregnancies
(left panel) occurred before 1990, and 24 (right
panel) in 1990 to 1991. (Used with permission
from Hou S, Am J Kid Dis 23:60, 1994.)
Table 3. Guidelines to optimize pregnancy outcome in the pregnant
dialysis patient
1. Prophylactic dialysis: blood urea maintained below 17 mmol/liter to
avoid polyhydramnios.
2. If hemodialysis is used: 5 to 7 dialysis sessions per week, with
bicarbonate buffer, minimal heparinization and slow-rate
ultrafiltration, in order to avoid dialysis hypotension and volume
contraction.
3. If peritoneal dialysis is used: decrease exchange volumes (e.g., to
1.5 liter) and increase exchange frequency.
4. Adequate calorie and protein supply: protein intake of 1 g/kglday
plus an additional 20 glday for fetal growth requirement;
supplements of hydrosoluble vitamins and zinc.
5. Adaptation of antihypertensive treatment (cf. Table 2).
6. Correction of anemia: supplements of iron and folic acid;
hemoglobin level no lower than 10 to 11 g/dl, with institution or
reinforcement of EPO therapy (requirements are 1.5 to 2 times
higher in pregnancy) whenever needed.
7. Prevention of metabolic acidosis.
8. Prevention of hypocaleemia by oral calcium carbonate
supplementation; avoidance of end-hemodialysis hypercalcemia.
9. Treatment of premature labor: prefer beta-agonists as first-line
drugs; NSAIDs to be used with great caution and for a limited
duration.
10. Reinforced fetal monitoring as soon as viability is reached.
verses the impaired fertility associated with ESRD and restores
libido and sexual activity. Thus, transplant recipients of childbear-
ing age should be informed that they are able to conceive and
should receive appropriate contraception.
Fetal perspective
Overall, of 3382 gestations in 2409 renal allograft recipients
recorded in a survey of the world literature from 1961 to 1994
[164], 34% terminated in therapeutic (20%) or spontaneous
(14%) abortion, but 93% of the gestations that continued beyond
the 20th gestational week ended successfully. However, the inci-
dence of preterm delivery (50%) and of growth retardation (40%)
with neonates of very low birth weight was high. Factors influenc-
ing fetal outcome are essentially the same as in women with
parenchymal renal disease. Hypertension, particularly when
Surviving
infants 52%n
Spontaneous
abortion 55%
Elective
abortion 4%
Spontaneous
abortion 35%
Before 1990 After 1990
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Table 4. Preconception guidelines for renal allograft recipients
1. Good general health for two years post-transplant.
2. Stable renal function with plasma creatinine <2 mg/dl ( 180
jsmol/liter) and, preferably, <1.5 mg/dl (135 .rmol/liter).
3. No evidence of graft rejection.
4. No or minimal proteinuria.
5. Absent of pelvicaliceal distension on a recent urogram or
echography.
6. Absent or easily managed hypertension.
7. Drug therapy reduced to maintenance levels: prednisone < 15 mg/
day, azathioprine  2 mg/kg/day, cyclosporine A 5 mg/kg/day.
term effect on graft survival, at least when the grafted kidney is
functioning well.
MANAGEMENT OF PREGNANCY IN WOMEN WITH
KIDNEY DISEASE
The main lesson gained from recent studies is that every
pregnancy in a woman with renal disease, especially when im-
paired renal function and/or hypertension is present, is a high-risk
pregnancy. Optimal management implies a multidisciplinary ap-
proach, the patient being followed in a tertiary care obstetrical
facility with experience in the care of high-risk pregnancies and
with an attendant neonatal intensive care unit, under the closely
coordinated care of the nephrologist and the obstetrician from
conception throughout the whole pregnancy [13, 176].
Preconception counseling
present at conception, is associated with an adverse perinatal
outcome [166]. Successful fetal outcome was achieved in 96% of
pregnancies started with a S < 125 mol/liter (1.41 mg/dl),
whereas this proportion fell to 75% in patients whose preconcep-
tion Sr level was in excess of this value, the upper 5Cr level
associated with a successful outcome being 160 to 180 /.Lmol/liter
(1.8 to 2 mg/dl) [164].
No abnormally high incidence of developmental abnormalities
has been reported in babies born to patients receiving either
azathioprine at a daily dose  2 mg/kg/day, or cyclosporine A up
to 5 mg/kg/day [167]. A longer interval between successful trans-
plantation and conception is associated with a lower incidence of
prematurity and low birthweight [168, 169], and an interval of at
least two years is a generally accepted recommendation [164].
Table 4 summarizes preconception guidelines for renal allograft
recipients as recommended by Davison [164].
Effect of pregnancy on allograft survival
Increases in GFR and renal plasma flow characteristic of
normal pregnancy are seen in transplant recipients, although to a
lesser degree [170]. The crucial question, however, is whether
pregnancy induces a risk of deterioration of graft function. Several
studies evaluated this risk by comparing long-term graft function
in pregnant and matched non-pregnant women. Salmela et al
reported a higher increase in 5Cr after pregnancy and a poorer
ten-year graft survival in 22 transplant patients who became
pregnant than in matched transplant women without pregnancy
[171]. However, other groups did not find a deleterious effect of
pregnancy on graft function. Rizzoni et al compared 53 pregnant
and 53 non-pregnant female transplant recipients over a four-year
follow-up period and disclosed no increased rate of graft deteri-
oration in pregnant women, provided 5Cr was < 160 imol/liter
(1.8 mg/dl) at conception [172]. Sturgiss and Davison compared
18 pregnant versus 18 non-pregnant women over a mean obser-
vation period of 12 years [173], recently up-dated to 15 years[174], and found that the mean S. values over the entire
follow-up did not significantly differ between the two groups. First
et al compared 18 women who became pregnant with 26 non-
pregnant women and 23 male transplant recipients; graft survival
with a mean post-transplant follow-up of 12 years did not differ
among the three groups [175]. Such concordant results authorize
the conclusion that pregnancy does not have a deleterious long-
Whenever possible, pregnancy should be planned in order that
conception takes place at a time when predictable risks are
minimal. Patients with primary renal disease and normal or near
normal renal function [SCr < 110 j.tmol/liter (1.24 mg/dl)] have
few contraindications to pregnancy [6, 9, 131. Patients with
systemic disease such as SLE or vasculitis should preferably
conceive after a stable remission has been obtained for at least
one year [103, 108, 116]. Patients with diabetic nephropathy
should achieve optimal glycemic control prior to conceiving [90,
96].
The most difficult decision concerns patients with already
impaired renal function. Pregnancy should be preferably under-
taken before 5Cr has reached 180 to 200 p.mol/liter (2.03 to 2.26
mg/dl), or Cr 40 ml/min/1.73 m2, in patients with primary
glomerular or non-glomerular renal diseases. Successful outcomes
have been obtained with 5Cr in excess of this level [141—144], but
both the risk of prematurity and fetal growth retardation, and of
accelerated deterioration of maternal renal function are high
when exceeds 250 to 300 jimol/liter (2.8 to 3.4 mg/dl). In
patients with diabetic nephrophathy, a level compatible with
an acceptable risk for the fetus and maternal renal function is
probably lower and pregnancy should preferably be discouraged
when Sr is above 130 to 150 mol/liter (1.5 to 1.7 mg/dl),
especially if severe hypertension coexists [101, 102]. In patients
with advanced renal failure or already on maintenance hemodi-
alysis or peritoneal dialysis, although a successful fetal outcome is
now less exceptional than in the recent past, it is often advisable
to defer pregnancy to after a successful transplantation [13, 831.
Patient and spouse must be clearly and comprehensively in-
formed of all the perspectives of pregnancy with respect to
expected fetal outcome and course of the maternal renal disease.
The final decision should be taken by the patient and spouse after
receiving full information [13].
Diagnosis of renal disease in pregnancy
By definition, preconception counseling is not feasible in pa-
tients in whom renal disease first manifests during pregnancy.
Presenting manifestations are proteinuria, the nephrotic syn-
drome, hypertension and/or elevated 5cr Such a constellation of
signs often mimics preeclampsia, especially when occurring in the
latter half of pregnancy. Antepartum kidney biopsy has been
advocated by some authors [1771, but most nephrologists restrict
biopsy to cases of rapidly progressive deterioration of renal
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function or of intense nephrotic syndrome occurring prior to 32
weeks of gestation [1781. The transjugular route may be preferred
in patients with thrombocytopenia and/or coagulation disorders.
Management guidelines
The most important factor of fetal prognosis, besides the level
of maternal renal function, is blood pressure. Most nephrologists
now agree that high blood pressure, especially when preexisting or
developing early in pregnancy, should be treated more aggres-
sively in patients with underlying renal parenchymal disease than
in patients with isolated essential hypertension [10, 13, 83]. The
problem of the optimal blood pressure level to achieve in preg-
nant patients with underlying renal disease, however, is still
debated. In our experience, the best fetal outcome in hypertensive
patients was observed when diastolic blood pressure could be
maintained therapeutically between 80 and 90 mm Hg.
The choice of the antihypertensive agent is important. This
topic has been recently reviewed [179—181]. There is consensus
that alpha-methyldopa should be used as the first-line agent
because its safety is well documented. Second-line agents added to
methyldopa may include the combined f3 and ts-adrenergic
blocker labetalol, or beta-blockers such as pindolol, metoprolol or
oxprenolol. Atenolol has been reported to adversely affect fetal
growth [181]. Although long-term studies on the tolerance of
hydralazine and calcium-channel blockers are not available, these
drugs may be used in patients insufficiently reponsive to the
above-mentioned, better studied drugs. Diuretics should be best
avoided in pregnancy in order to prevent volume contraction.
ACEIs, which may induce irreversible anuria in the neonate and
are possibly teratogenic are contraindieated in pregnancy, at least
in the last two trimesters [182, 183]. Calcium supplementation has
been reported to improve blood pressure and prevent preeclamp-
sia [1841, and is especially indicated in dialysis patients [146, 152].
Use of low-dose aspirin to prevent onset of preeclampsia is
debated. Because the relative risk of preeclampsia is at least five
times greater in patients with preexisting hypertension, low dose
aspirin (75 to 100 mg/day) should be indicated in hypertensive
patients from the 12th week of pregnancy [179], and earlier in
SLE patients with the presence of anticardiolipin antibodies or
the lupus anticoagulant, even in the absence of hypertension, to
prevent placental infarction and ischemia [lii, 114].
Fetal monitoring and delivery
Serial assessment of fetal growth and well-being is essential in
pregnant patients with renal disease because of the increased risk
of intrauterine growth retardation and stillbirth [13, 831. Uterine
artery waveform indices at 19 to 24 weeks gestation may be useful
for the prediction of preeclampsia and IUGR [1851, although
definitive evidence is still lacking. Fetal growth should be ultra-
sonographically screened beyond 26 weeks of gestation. If IUGR
is detected, fetal well-being evaluations including fetal cardioto-
cography, amniotic fluid index, umbilical artery and fetal cerebral
arteries velocity should be performed [176].
A substantial proportion of neonates born to mothers with
impaired renal function are very premature, and often of very low
birthweight. Extreme prematurity is associated with a high pen-
natal mortality rate, and few infants born before the 25th gesta-
tional week survive without severe encephalic sequelae [186].
Morbidity and mortality of immature neonates are related to pen-
or intraventricular hemorrhage, peniventricular leukomalacia, ret-
inopathy, enterocolitis, chronic lung disease and acute respiratory
distress syndrome. Only the latter is preventable by antenatal
glucocorticoid administration, which is indicated when gestational
age is critical (25 to 34 weeks) in order to enhance fetal pulmonary
maturation [1871. Betamethasone or dexamethasone should be
given every 12 hours for two days. The resulting reduction in
respiratory morbidity is associated with reductions in neurological
complications.
In cases of threatening premature contractions, beta-adrenergic
receptor agonists may stop premature labor for a few days and
thus allow antenatal corticosteroid administration. If the use of
beta-adrenergic agonists is contraindicated, especially in hyper-
tensive patients, nifedipine should be used [188]. As discussed
above, non-steroidal antiinfiammatory drugs should be used with
great caution. Although indomethacin has been considered a
useful tool to treat premature labor, many neonatologists cur-
rently discourage its use since it carries the risk of neonatal renal
failure, in addition to premature closure of the ductus arteriosus.
Corticosteroids may be given during lactation. However, breast-
feeding is contraindicated in women receiving non-steroidal anti-
inflammatory drugs, cyclosphosphamide, azathioprine, cyclospor-
inc or antimalarial drugs [1 89—191].
CONCLUSION
In conclusion, the present state of our knowledge supports a
more optimistic view of pregnancy in patients with renal disease
than in the recent past, especially with respect to fetal outcome
[192]. Factors governing fetal and maternal prognosis are now
well defined. In the majority of patients with primary renal disease
who have preserved renal function and well-controlled blood
pressure, pregnancy is essentially successful and does not alter the
natural course of maternal renal disease. Even in patients with
already impaired renal function and/or hypertension, fetal out-
come has significantly improved in recent years thanks to contin-
uous progress in obstetrics and neonatology and better manage-
ment of hypertension and renal failure. A risk of unsuccessful
fetal issue and of deterioration of maternal renal disease still
persists, however, of which the patient and spouse must be clearly
informed. Multidisciplinary management, preferably in a tertiary
care facility, with close coordination between the nephrologist and
the obstetrician from the beginning of gestation is the key factor
to optimize the issue of such high risk pregnancies. In view of the
continuing progress in obstetrics and neonatology, as well as in
our knowledge of factors governing fetal development in a hostile
hypertensive and/or urcmic milieu, one may expect that an
increasing number of women in the near future will be able to
obtain motherhood despite underlying renal disease.
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